Groupe Hospitalier Bretagne Sud — Clinical Trial Site

54 Registered trials

21 Currently recruiting

Organisation

Groupe Hospitalier Bretagne Sud

Location

Lorient, France

Identifier

ORG-100043984

Address

5 Avenue Etienne Francois De Choiseul, 56100, France

Departments

2107: Dermatology
Anesthésie-Réanimation
Cardiology
Gastroenterology
Hématologie
Hematology
Hepato-gastroenterology
Hôpital du Scorff - Service d'Oncologie Médicale
Medical Oncologist
Medical Oncology
Medical Oncology Department
N/A
Neurology
Oncologie
Oncologie Médicale
Oncologie Radiothérapie
Oncologie-Radiothérapie-Hématologie
oncologist
Oncology
Oncology / Radiotheray
ONCOLOGY GASTRO ENTEROLOGY
Oncology Radiotherapy
Oncology-Radiotherapy
Radiothérapie
Radiotherapy
Radiotherapy Oncology
Réanimation et soins continus
Service d'Oncologie Medicale
Service d'Oncologie Radiothérapie
Service de Dermatologie
Service de Pneumologie
Service Médecine Hématologie – VIH

Clinical trials at this site (54)

Search interface

Corticoid Therapy in Acute Myocarditis Pending

2024-510602-90-00 Patients presenting with acute myocarditis proven by ca 5
MInimal residual Disease Adapted Strategy / IFM 2020-02 Pending

2024-513889-19-00 Multiple Myeloma 5
Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable high grade gliomas patients Pending

2024-514144-85-02 Glioblastoma 3
Skipping Hormone Therapy in Low-Risk Early Breast Cancer Pending

2025-523683-20-00 Postmenopausal patients with small (pT1a-b pN0) hormone 4
TAILORswitch (PADA-2): rising ctDNA to tailor endocrine therapy switch in patients with ER+/HER2- metastatic breast cancer. Pending

2025-524213-84-00 Patients with advanced or metastatic ER+ HER2- breast c 5
Early Corticosteroids in Severe Influenza Pneumonia, a phase III randomized controlled trial Pending

2025-524976-40-00 patients with influenza-induced acute hypoxemic respira 5
Phase III randomized international open label clinical trial of treatment Intensification with docetaxel plus apalutamide in patients with m… Recruiting

2025-524408-30-01 Metastatic hormone-sensitive prostate cancer 5 2026-06-05
Phase 3 study comparing ivonescimab alone or ivonescimab with ligufalimab versus pembrolizumab for the first-line treatment of recurrent and… Recruiting

2025-522996-27-00 recurrent and/or metastatic squamous cell carcinoma of 5 2026-05-05
Trial of Two Adagrasib Dosing Regimens in NSCLC with KRAS G12C Mutation Recruiting

2023-503523-25-00 Non-small cell lung cancer 4 2024-02-29
Randomised phase III trial of ADT +/- darolutamide in frail men with castration-naïve de novo metastatic prostate cancer Recruiting

2022-502425-18-00 Adenocarcinoma of the prostate 5 2022-04-19
A multi-center phase III randomized study comparing continuous versus fixed duration therapy with Daratumumab, Lenalidomide, and Dexamethaso… Recruiting

2024-511855-16-00 Onco-hematology 5 2019-07-25
PRODIGE 88-CIRCULATE PAC: Phase III multicentric, open-label, randomized study to investigate the efficacy of chemotherapy in patients with … Recruiting

2023-505046-26-00 Colon carcinoma 5 2026-05-07
Platform study to evaluate the efficacy and safety of investigational compound(s) in patients with moderate to severe atopic dermatitis Recruiting

2024-519081-49-00 Moderate to severe atopic dermatitis 4 2025-10-28
Clinical trial comparing induction treatment with EGFR-ADC MRG003 alone or in combination with the anti PD1 Pucotenlimab, followed by radioc… Recruiting

2023-510558-18-00 locally advanced head and neck squamous cell carcinoma 4 2025-10-13
ENGIC 01 - COLOSOTO: A single-arm phase II study evaluating 5-fluorouracil plus Panitumumab (anti-EGFR) and Sotorasib (KRAS G12C inhibitor) … Recruiting

2024-514030-20-00 colorectal cancer 4 2025-08-29
Digital monitoring of self-reported symptoms by patients treated with Cabozantinib plus Nivolumab for advanced clear-cell renal carcinoma: T… Recruiting

2024-518991-30-00 kidney cancer 6 2025-07-17
IFM2024-06 : A multi-center, open-label, phase 2 randomized study of elranatamab plus lenalidomide versus daratumumab plus lenalidomide as p… Recruiting

2024-517325-43-00 multiple myeloma 4 2025-06-19
Treatment with darolutamide +/- radiation therapy for patients with a castration resistant cancer and metastases detected by functional imag… Recruiting

2023-509787-15-00 Patients with localised prostate cancer and high-risk f 5 2025-02-17
PRODIGE 90 - FFCD 22024 - PREDIR-NEOREC - Neoadjuvant dostarlimab with short course radiotherapy in a watch-and-wait strategy for microsatel… Recruiting

2024-510772-20-00 Rectal cancer locally advanced with microsatellite unst 4 2025-02-06
Free regimen of Dexamethasone as initial therapy for advanced relapsed/refractory multiple myeloma: an open-label randomized, non-inferiorit… Recruiting

2024-510981-18-00 Multiple Myeloma Multiple myeloma (MM) is a B cell mali 5 2024-12-12
FIRST LINE CHEMOTHERAPY FOR METASTATIC GASTRO ENTERO PANCREATIC NEUROENDOCRINE CARCINOMA Recruiting

2024-515300-39-00 METASTATIC GRADE 3 POORLY DIFFERENTIATED NEUROENDOCRINE 4 2024-10-18
Treatment with darolutamide +/- radiation therapy for patients with a castration resistant cancer and metastases detected by functional imag… Recruiting

2023-507482-26-00 Castrate-resistant prostate cancer with oligometastases 5 2024-10-04
PRODIGE 70 - CIRCULATE - CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II Recruiting

2024-515297-27-00 colon carcinoma 5 2024-08-14
Treatment of microstellite stable metastatic colorectal cancer presenting high immune infiltrate with chemotherapy (XELOX or FOLFOX Bevacizu… Recruiting

2024-515788-73-00 MICROSATELLITE STABLE (MSS) METASTATIC COLORECTAL CANCE 4 2024-07-30